Solid Biosciences

Solid Biosciences is looking forward to attending the 2026 Leerink Partners Therapeutics Forum in Boston on July 15, where members of the management will participate in 1x1 investor meetings. If you will be attending, we’d welcome the chance to connect. #SLDB #SolidBiosciences #Biotech #RareDisease #LeerinkPartners

We are proud to sponsor the 2026 What NOW? Virtual Conference hosted by @TeamJosephInfo, taking place July 15–16. Led by a committee of older adolescents and adults living with Duchenne, this event focuses on navigating the transition into adulthood, exploring key topics such as independence, higher education, career paths and relationships. You can learn more and register for the conference here: teamjoseph.org/what-now-confe… #WhatNOW2026 #Duchenne #RareDiseaseCommunity

Our Head of Corporate Strategy and Business Development, Shuli Roditi-Kulak, MD, MBA, recently joined leaders from across the industry at the @IAmBiotech (BIO) International Convention to discuss the future of biotech innovation and leadership. During the session, "At the Helm of Biopharma: Insights from Women Leading Science, Strategy and Scale," Shuli shared her perspective on how the biotech ecosystem must evolve to meet the next era of innovation. As scientific complexity increases, radical collaboration can unlock new models that empower companies to leverage shared knowledge and capabilities to accelerate progress for patients. Our #SolidInside efforts reflect this philosophy. We are working to expand access to next-generation enabling technologies that create new pathways for partnership across precision genetic medicine, allowing companies to focus more resources on innovation and less on rebuilding foundational infrastructure. #BIO2026

Thank you to @ParentProjectMD (PPMD) for a meaningful and engaging 2026 Annual Conference. Our team was grateful for the opportunity to connect with patients, families, advocates, clinicians and researchers from across the Duchenne community. During the conference, Kevin Flanigan, MD, of @nationwidekids and Principal Investigator in the Phase 1/2 INSPIRE DUCHENNE clinical trial, presented an overview of the SGT-003 development program during the Gene Therapy: Today & Tomorrow session. The presentation helped foster important discussions about ongoing research and the future of Duchenne treatment development. We're thankful to PPMD for bringing the community together and look forward to continuing these important conversations in support of individuals and families impacted by Duchenne. #PPMD2026 #Duchenne #GeneTherapy #RareDisease #DuchenneCommunity

As we head into the @ParentProjectMD (PPMD) Annual Conference, we are sharing the latest update with the Duchenne Community, including an overview of recent progress in our SGT-003 clinical development program. We are deeply grateful for our partnerships with patients, families and our clinical sites, and look forward to engaging at PPMD this weekend. Read more here: solidbio.com/letter-to-the-…

#TeamSolid was proud to take part in the @BAA's 10K, presented by Mass General Brigham Cancer Institute! All funds raised will support efforts to advance groundbreaking research, deliver leading-edge care, and improve outcomes for patients and families facing cancer. Congratulations to everyone who raced and thank you to the B.A.A. for bringing together such an incredible event and community. #BAA10K #MassGeneralCancerInstitute #CardiacHealth

We’re proud to be attending, sponsoring and exhibiting at @ParentProjectMD's 2026 Annual Conference, taking place June 25–27 in Orlando. This important meeting brings together the Duchenne community to connect, learn and discuss advancements toward new treatments. We look forward to engaging with patients, families, advocates, clinicians and partners throughout the conference. If you’re attending, stop by our exhibit table #4 to connect with the Solid Biosciences team. Learn more: parentprojectmd.org/events/ppmds-2… #PPMD2026

Our Head of Corporate Strategy and Business Development, Shuli Kulak, M.D., will participate in @IamBiotech's International Convention breakout session, At the Helm of Biopharma: Insights from Women Leading Science, Strategy, and Scale. To learn more about the session, visit: convention.bio.org/2026-sessions-… #BIO2026

Looking forward to the conversations and connections at #BIO2026 next week. If you’re in the genetic medicine space and want to chat about platform partnerships or our pipeline, let's find some time to connect in San Diego. #GeneTherapy #BiotechInnovation Reach us at businessdevelopment@solidbio.com or through the BIO Partnering™ system, convention.bio.org/partner

Welcome to our new Executive Director of Government Affairs, Stacey Frisk, who joins us from the Rare Disease Company Coalition. Stacey has already hit the ground running and recently moderated a panel at the @OrphanConf USA 2026 focused on the opportunities and challenges surrounding newborn screening for rare diseases. The conversation explored how policy advancements, infrastructure improvements and emerging technologies can help create a more equitable path to early diagnosis. Stacey highlighted the importance of early diagnosis in Duchenne muscular dystrophy and Solid's role in supporting the community-led effort, spearheaded by @ParentProjectMD, to advance Duchenne's nomination to the Recommended Uniform Screening Panel (RUSP). Together, these efforts reflect a commitment to expand access to early diagnosis and improve outcomes for families affected by rare diseases. #WODC #WorldOrphanDrugCongress #RareDisease #NewbornScreening #Duchenne #HealthPolicy #SolidInside #WorldOrphanUSA

We’re proud to share moments from the Team Solid at the recent Bio-Ball event! This event brought together the biotech community to support @SpOlympicsMA and the athletes who inspire us every day. It was an honor for our team to participate, compete and celebrate the power of inclusive sports. Huge thanks to the organizers and everyone who made this event unforgettable. #BIOBall #SpecialOlympics #SolidBiosciences #Community

It’s time to get ready for #BIO2026! We are excited to connect with industry leaders and innovators who share our goal of accelerating toward the future of precision genetic medicine. If you are interested in learning about next-generation #SolidInside technologies, including our proprietary, muscle-tropic capsid, POLARIS-101™, as well as our repository of preclinical reference data, CMC expertise and our innovative pipeline, we’d love to meet you. Our CFO, Kevin Tan, and our Head of Corporate Strategy and Business Development, Shuli Roditi-Kulak, MD, MBA, will be attending. Reach out to meet with us! #POLARIS101 #GeneTherapy, #BiotechInnovation, #GeneticResearch, #LifeSciences #PharmaPartnering #BusinessPartnering

We’re proud to support the @JettFoundation as a sponsor of the 25th Anniversary Silver Soirée on June 11. As a longstanding partner, we’re honored to stand alongside an organization that is making a meaningful difference for individuals and families impacted by Duchenne. Events like this bring the community together to celebrate progress, resilience and the work still ahead. Thank you to the Jett Foundation for your continued partnership. We look forward to an impactful evening! #SolidBiosciences #JettFoundation #SilverSoiree #Duchenne #Partnership #BiotechCommunity

Solid Biosciences is heading to the @GoldmanSachs Global Healthcare Conference in Miami on June 8. Join our President and CEO, Bo Cumbo, for a corporate presentation at 4 PM ET, where he will share updates across our pipeline and strategic priorities. Tune in here: event.webcasts.com/starthere.jsp?… #GoldmanSachs #GeneticMedicine #Biotech #Solidinside